Skip to content
Peptide research

Chonluten

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A synthetic tripeptide marketed as a bioregulator for bronchial mucosal support and anti-inflammatory, antioxidant action. The case is almost entirely preclinical and mechanism-only, randomized human trials remain unverified, and nearly all research traces to one lab with no independent replication. Long-term human safety is unknown. Not an approved drug in the US, and unregulated products sold online are of uncertain purity.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Anti-inflammatory modulation

    Low

    Reduced TNF-alpha and IL-6 release in one human immune cell study, not independently replicated.

  • Bronchial mucosal support

    Speculative

    Based on a developer comparison with standard-treatment controls; randomization was not reported and benefit remains unconfirmed.

  • Antioxidant gene regulation

    Speculative

    Mentioned only in review articles; no primary study has measured this effect directly.

Evidence limits

Evidence Level
Preclinical

Evidence consists primarily of one well-designed in vitro study (Avolio et al. 2022, IJMS) using THP-1 monocytic cells, plus preclinical animal studies and mechanistic investigations from Khavinson's group. Most claims about bronchial mucosal support derive from the broader Khavinson bioregulatory peptide framework rather than Chonluten-specific clinical trials. The related tetrapeptide Bronchogen (AEDL) has more published data on bronchial gene expression. Evidence is limited and predominantly from a single research group.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Human evidence is limited to weak developer reports; randomized clinical benefit remains unconfirmed.

    High
  • Almost all research originates from a single group (Khavinson / St. Petersburg Institute of Bioregulation and Gerontology) — no independent replication

    High
  • Long-term safety profile in humans is unknown

    Moderate
  • Potential allergic reactions or individual intolerance

    Low
  • Contraindicated during pregnancy and lactation (per manufacturer)

    Low
  • Quality varies among unregulated products sold online — no pharmaceutical-grade standardization

    Moderate
  • Increased apoptosis observed in vitro (Avolio et al. 2022) — implications for healthy tissue unclear

    Low
  • Gene expression modulation effects on pre-existing conditions (e.g., cancer) are unstudied

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.